Donate Your Heartbeats App
Apple Watch app for anonymous ECG donation to advance cardiology research
Software · Cloud SaaSCompany source
Company profile
About Idoven
Idoven is a pioneering health AI company that has developed the world's first cardiology-as-a-service platform powered by artificial intelligence. The company's flagship product, Willem™, is a CE-marked Class IIa medical device platform that provides AI-powered ECG analysis to augment clinicians' ability to identify, triage, and diagnose cardiac conditions at scale. Named after Willem Einthoven, the father of the electrocardiograph and Nobel Prize winner, the platform can detect 22 cardiac patterns automatically with cardiologist-level accuracy across various ECG recording device types including 12-lead resting ECGs, ambulatory devices (holter and patch), and insertable cardiac monitors. Idoven serves three primary market segments: MedTech companies seeking digital diagnostics and cloud-based ECG interpretation; life sciences organizations developing digital biomarkers for cardiotoxicity monitoring and risk stratification; and organizations implementing preventative screening programs with remote patient monitoring. The company's AI models are trained on one of the most diverse and longest ECG databases globally, comprising 1.8 million ECG hours from 28,500+ subjects, manually annotated specifically for AI training. Idoven collaborates with clinical partners in more than 20 countries across Europe and beyond, working on clinical studies, research consortia, and real-world deployments. The company has gained significant recognition through its partnership with Iker Casillas, the World Cup-winning goalkeeper who suffered a heart attack in 2019 and now relies on Idoven for cardiac care. Together with the Iker Casillas Foundation, Idoven launched the #donateyourheartbeats movement, allowing individuals to contribute ECG data from Apple Watch devices to advance cardiovascular research. Idoven is headquartered at Google for Startups Campus in Madrid, Spain, and has published over 35 papers in top-tier scientific journals while developing multiple prediction models targeting cardiovascular disease.
Company description Idoven official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Work at Idoven?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Arrhythmias
- Atrial fibrillation
- Cardiac amyloidosis
- Cardiotoxicity
- Cardiovascular diseases
- Heart failure
- Stroke
Who it serves
- Cardiology departments
- Health systems
- Life Sciences companies
- MedTech companies
- Pharmaceutical companies
- Primary care providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: EHR systems, Electronic Health Record systems, Home Monitoring systems.
Geographic context
MarketsEurope · Global · Italy · Netherlands · Spain · Sweden · United States
Company sourceOfficial website
Company milestones
Platform expansion
AstraZeneca and Idoven launched CONCERTO project (2024-2027) to improve early diagnosis of amyloidosis. FAITHFUL Consortium launched (2024-2025) with €1.7 million from EIT Health Spain involving 14 international institutions. Featured on cover of Forward: Unlocking Europe's AI Potential (September 2025).
Partnerships
Recorded partners
- AstraZeneca
- EIT Health Spain
- Google for Startups Campus
- Iker Casillas Foundation
- MAESTRIA H2020 Consortium
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Life Sciences Solution
ECG-based digital biomarkers for disease prediction and cardiotoxicity monitoring
Platform · Cloud SaaSCompany source
Life Sciences Solutions
ECG-based digital biomarkers for disease prediction and cardiotoxicity monitoring
Platform · Cloud SaaSCompany source
MedTech Solution
Digital diagnostics and cloud-based ECG interpretation for medical device companies
Platform · Cloud SaaSCompany source
MedTech Solutions
Digital diagnostics and cloud-based ECG interpretation for medical device companies
Platform · Cloud SaaSCompany source
Preventative Screening Programs
Remote ECG monitoring and digital screening for employee health programs
Service · Cloud SaaSCompany source
Willem
AI-powered ECG analysis platform for cardiology-as-a-service
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
40% reduction in hospitalizations
FAITHFUL Consortium heart failure detection in primary care
Cardiologist-level accuracy
Detection of 22 cardiac patterns
Minutes
Time to deliver ECG analysis results
AstraZeneca
CONCERTO project to improve early diagnosis of patients with cardiac amyloidosis using AI-powered ECG analysis
Partnership launched to detect subtle patterns signaling early signs of amyloidosis that are often missed by experienced cardiologists, addressing diagnostic delays of up to 4 years
FAITHFUL Consortium
Augmenting heart failure detection in primary care with AI ECG platform across 14 leading international institutions
Anticipated 40% reduction in hospitalizations leading to significant healthcare cost savings, backed by €1.7 million from EIT Health Spain
Iker Casillas
Personal cardiac monitoring following heart attack at age 38 during training on May 1, 2019
Ongoing cardiac care and monitoring; partnership with Iker Casillas Foundation to impact vulnerable groups at high risk of cardiovascular diseases
Iker Casillas Foundation
Personal cardiac monitoring and cardiovascular disease prevention research for vulnerable groups at high risk
Partnership established to impact lives of vulnerable groups at high risk of cardiovascular diseases through the #donateyourheartbeats movement
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Idoven
Recent articles published on Idoven's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.